In prostate cancer, radiolabelled antibodies like 177Lu-PSMA-617 have emerged as potent tools, capitalizing on the overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells [98], as depicted in Fig. 3. This evidence concerns the gene FOLH1 and prostate cancer.